Related Experiment Video
Updated: Aug 8, 2026

11:10
Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice
Published on: November 16, 2011
Ghrelin differentially affects hepatic and peripheral insulin sensitivity in mice
A C Heijboer1, A M van den Hoek, E T Parlevliet
1Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, P.O. Box 9600, 2300 RC, Leiden, The Netherlands. a.c.heijboer@lumc.nl
Diabetologia
|February 18, 2006
Summary
Ghrelin enhances glucose disposal but impairs insulin
Area of Science:
- Metabolic research
- Endocrinology
- Glucose metabolism
Background:
- Ghrelin, a peptide hormone, plays a role in appetite regulation.
- Its effects on glucose metabolism and insulin action are not fully understood.
- Investigating ghrelin's impact on insulin sensitivity is crucial for metabolic health research.
Purpose of the Study:
- To evaluate ghrelin's effects on insulin-mediated glucose production and disposal in mice.
- To determine if the growth hormone secretagogue (GHS) receptor mediates ghrelin's actions on insulin.
- To explore the role of des-ghrelin (unacylated ghrelin) in this context.
Main Methods:
- Intravenous infusion of ghrelin, GHRP-6, des-ghrelin, or vehicle in mice.
- Measurement of endogenous glucose production and glucose disposal using radiolabeled glucose during hyperinsulinemic-euglycemic clamp.
- Assessment of tissue-specific glucose uptake in muscle and adipose tissue.
Main Results:
- Ghrelin significantly increased glucose disposal and muscle glucose uptake.
- Ghrelin impaired insulin's ability to suppress endogenous glucose production.
- GHRP-6 had no effect on insulin action; des-ghrelin hindered hepatic insulin action.
Conclusions:
- Ghrelin modulates insulin action by enhancing glucose disposal and reducing hepatic insulin suppression, independent of food intake or body weight.
- These effects are likely not mediated by the GHS receptor.
- Des-ghrelin counteracts ghrelin's inhibitory effect on hepatic insulin action.
Related Concept Videos
Insulin: The Receptor and Signaling Pathways
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but this inhibition is released...
Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...

